These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11154251)

  • 1. The discount rate in the economic evaluation of prevention: a thought experiment.
    Bonneux L; Birnie E
    J Epidemiol Community Health; 2001 Feb; 55(2):123-5. PubMed ID: 11154251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial.
    Peels DA; Hoogenveen RR; Feenstra TL; Golsteijn RH; Bolman C; Mudde AN; Wendel-Vos GC; de Vries H; Lechner L
    BMC Public Health; 2014 Oct; 14():1099. PubMed ID: 25342517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Money for health: the equivalent variation of cardiovascular diseases.
    Groot W; Van Den Brink HM; Plug E
    Health Econ; 2004 Sep; 13(9):859-72. PubMed ID: 15362178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ; Vander Hoorn S; Jackson RT
    Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment.
    Kaper J; Wagena EJ; van Schayck CP; Severens JL
    Pharmacoeconomics; 2006; 24(5):453-64. PubMed ID: 16706571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs.
    Rasmussen SR; Thomsen JL; Kilsmark J; Hvenegaard A; Engberg M; Lauritzen T; Søgaard J
    Scand J Public Health; 2007; 35(4):365-72. PubMed ID: 17786799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
    Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
    Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.